These findings are, however, challenged by the observation of no impaired mitochondrial or glycolytic function in iPSC MNs derived from ALS FUS mutant patients which produce similar FUS proteinopathies as seen in FTD patients (Vandoorne et al., 2019). This evidence concerns the gene FUS and amyotrophic lateral sclerosis.